[{"orgOrder":0,"company":"Tiumbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tiumbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"SK Chemicals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tiumbio \/ SK Chemicals","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ SK Chemicals"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiumbio \/ Hansoh Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Hansoh Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Merigolix

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : HS-10518 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated for improvement of pregnancy rate per cycle.

                          Product Name : HS-10518

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Merigolix

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : TU2670 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated in females with endometriosis-associated-pain.

                          Product Name : TU2670

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 05, 2024

                          Lead Product(s) : Merigolix

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.

                          Product Name : TU2670

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 29, 2023

                          Lead Product(s) : Merigolix

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : SK Chemicals

                          Deal Size : Undisclosed

                          Deal Type : Private Placement

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.

                          Product Name : TU2670

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 07, 2023

                          Lead Product(s) : Merigolix

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Hansoh Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank